OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Neurology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Facial Numbness, Dysarthria, Muscle Atrophy, and Weakness in a Young Patient	461
Adequate Initial Dosage and Tapering Methods of Steroids to Reduce the Total Corticosteroid Dose in Myasthenia Gravis	426
Diplopia and Ptosis in an Older Woman	375
Early Posttraumatic Seizures—Putting Things in Perspective	371
Rizatriptan vs Placebo for Attacks of Vestibular Migraine	321
Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration	321
Origin of Transthyretin in Cerebral Amyloid Angiopathy	267
Error in Author Name	214
Equipping AI for Unbiased and Inclusive Neurology	205
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation	203
Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis	197
Ghrelin for Neuroprotection in Post–Cardiac Arrest Coma	196
Automated Imaging Differentiation for Parkinsonism	189
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With Attendance	188
Somebody to Love	188
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention	185
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation	184
Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy	182
Association Between Increased Seizures During Rewarming After Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy and Abnormal Neurodevelopmental Outcomes at 2-Year Follow-up	182
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis	179
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials	173
Alternate Hemibody Hyperkinetic and Hypokinetic Movement Disorders Due to Strategic Lesions in Cerebral Toxoplasmosis	170
JAMA Neurology	163
Magnetic Resonance Imaging Features of Tropical Candidal Meningoencephalitis	161
Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach	158

Time to Change the Current Clinical Classification of Multiple Sclerosis?	150
Time From Hospital Arrival Until Endovascular Thrombectomy and Patient-Reported Outcomes in Acute Ischemic Stroke	150
JAMA Neurology	149
Is It Really Itching?	148
Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease	139
The Neurologist’s Imperative in Brain Death	138
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis	132
Functional Outcomes in Conservatively vs Surgically Treated Cerebellar Infarcts	132
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease	129
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation	124
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers	123
Error in Abstract	122
Retinal Hemorrhage Associated with Human Granulocytic Anaplasmosis	122
Do Neurologists Need a Goldwater Rule?	119
Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care?	117
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy	115
Disentangling Workflow Paradigms and Treatment Decision-making in Acute Ischemic Stroke	112
Error in Figure	110
Error in Additional Contributions	109
Histologic Anatomy of Neurocysticercosis	109
Association of Cardiovascular Events With Spouse’s Subsequent Dementia	106
Is It Really Itching?—Reply	98
Sleep Recording for the Diagnosis and Treatment of Paraplegia	98
Spinal Cerebrospinal Fluid Leak Mimicking a Cerebellopontine Angle Tumor	98
JAMA Neurology	97
β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions	97
Error in Figure	93
Functional Seizures—A Critical Comorbidity Overlooked in Epilepsy Research—Reply	91
Visual Neglect After an Isolated Lesion of the Superior Colliculus	91
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy	90
Intra-Arterial Tenecteplase After Successful Reperfusion in Large Vessel Occlusion Stroke	90
Spontaneous AICA Dissection Presenting With Isolated Audiovestibular Loss	88
Role of the X Chromosome in Alzheimer Disease Genetics	87
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias	87
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease	86
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology	85
Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke	85
Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core	84
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum	83
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion	83
Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment	82
Tackling the Unmet Therapeutic Needs in Nonsurgical Treatments for Epilepsy	81
Acute Myelopathy in a Man With Cutaneous Papules	80
JAMA Neurology	77
JAMA Neurology	76
Error in Text	76
Magnetic Resonance Imaging Features of GABA-A Receptor Antibody-Mediated Encephalitis	76
Error in Figures	75
Peripheral-Type Facial Paralysis and Unilateral Hemisphere Hemorrhage	75
Perceived CTE and Suicidality—Is Perception Reality?	75

Error in Key for Figure 3	75
Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease	74
AI Devices in Neurology—Moving From Diagnosis to Prognosis	74
A Rare Neurological Presentation of Kikuchi-Fujimoto Disease	73
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome	73
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis	72
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients	72
The New Era of Automated Electroencephalogram Interpretation	72
Bibrachial Amyotrophy Due to Spontaneous Spinal Cerebrospinal Fluid Leak	69
Visualization of Parkinsonian Tongue Tremor on Ultrasonography	69
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis	69
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers	69
Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	69
The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo	68
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease	68
Comparison of Perinatal Outcomes for Women With and Without Epilepsy	68
Functional Impairment in Individuals With Prodromal or Unrecognized Parkinson Disease	67
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke	67
Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome	67
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura	66
Repairing Our View of Dementia	66
The Choreoathetotic Movement of Paroxysmal Nonkinesigenic Dyskinesia	64
Error in Text	63
Concerns Remain Regarding Ambient NO₂ Exposure and the Risk of Parkinson Disease—Reply	63
Livedo Reticularis—A Presenting Sign of Neuromyelitis Optica Spectrum Disorder	62
JAMA Neurology Peer Reviewers in 2021	62
Error in Title	61
Addition of Video Titles	59
SARS-CoV-2 Vaccination and Neuroimmunological Disease	58
Adverse Childhood Experiences, Toxic Stress, and Trauma-Informed Neurology	58
Expanding the Prion Paradigm to Include Alzheimer and Parkinson Diseases	58
Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies	58
Benefits and Risks of Periconceptional Folic Acid Supplementation—Reply	58
Cerebral Amyloid Angiopathy—How to Translate Updated Diagnostic Criteria for This Multifaceted Disorder to Clinical Practice?	57
Possible Explanations for Hearing Loss in Parkinson Disease	57
Cognitive Behavioral Therapy for Veterans With Comorbid Posttraumatic Headache and Posttraumatic Stress Disorder Symptoms	57
Benefits and Risks of Periconceptional Folic Acid Supplementation	57
IWG and AA Criteria—Where the Differences Matter—Reply	57
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest	56
Association Between Acute Myocardial Infarction and Cognition	55
Life Expectancy for Patients With Sporadic Creutzfeldt-Jakob Disease	54
Reimagining the Treatment of Distal and Medium Vessel Occlusion Strokes	53
Coma Prognostication After Acute Brain Injury	53
Choosing the Best Antiseizure Medication—Can Artificial Intelligence Help?	53
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis	53
Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow	53
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	53
A Woman With Eosinophilic Brainstem Meningoencephalitis	52
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis—Variations in Real-World Experience—Reply	52
The Perils and Pitfalls of Global Engagement	52
Monogenic Stroke—Can We Overcome Nature With Nurture?	52
JAMA Neurology	52
How Is the X Chromosome Involved in Alzheimer Disease?	51
Addition of Nonauthor Collaborators and a Supplement	49
Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness	48
Views From Both Sides of the White Coat	47
Transcarotid Artery Revascularization for Stroke Prevention—Multiple Elephants in the Room	47
Errors in Figure 2 and the Short Title	46
Gantenerumab in Dominantly Inherited Alzheimer Disease—Reply	45
Structural Inequities for Historically Underserved Communities in the Adoption of Stroke Certification in the United States	45
Medical Forecasting—A Skill Set Worthy of Attention	45
Error in Author Affiliation	45
Citius, Fortius, Altius—Understanding Which Components Drive Exercise Benefits in Parkinson Disease	45
Chronic Immune Peripheral Nerve Myelinopathies—A Plea for Precision	45
Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid-β and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia	44
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage	44
TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis	44
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	44
Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management	44
GLP-1 RAs for Idiopathic Intracranial Hypertension—Time for a Trial	43
Statewide Emergency Medical Services Protocols for Suspected Stroke and Large Vessel Occlusion	43
The End Justifies the Means—A Call for Nuance in the Increasing Nationwide Adoption of Stereoelectroencephalography Over Subdural Electrode Monitoring in the Surgical Evaluation of Intractable Epileps	43
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors	43
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios	42
Modern Neurology Training Is Failing Outpatients	42
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	41
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis	41
Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy	40
Discerning the Role of Autoimmunity and Autoantibodies in Epilepsy	40
Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria	40

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	40
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis	40
Error in Title	39
Bilateral Complete Ophthalmoplegia in a 50-Year-Old Man	39
Error in Figures 2 and 3	38
A 51-Year-Old Woman With Abnormal Corpus Callosum Signal	38
JAMA Neurology	38
An Acetylcholine M₁ Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment	37
JAMA Neurology	37
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection	37
Error in Open Access Status	37
Genome Sequencing After Exome Sequencing in Pediatric Epilepsy	37
Acute Ischemic Stroke Care Quality Improvement	37
Multimodal Neuroimaging of Intimal Flap in a Basilar Artery Dissection	37
Venture Capital Investment in Neurology Companies	36
Risks of Expanded Medicare Coverage of Carotid Artery Stenting	35
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes	35
Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants	35
Multisite Skin Biopsies vs Cerebrospinal Fluid for Prion Seeding Activity in the Diagnosis of Prion Diseases	35
Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy	35
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia	35
Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease	35
Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death	34
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia	34
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis	34
Neurologic Complications of Smallpox and Monkeypox	34
CT Perfusion Imaging After Selection for Late-Window Endovascular Stroke Treatment	34
White Matter Tract Density Index Prediction Model of Overall Survival in Glioblastoma	33
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease	33
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk	32
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease	32
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease	32
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine	32
Batoclimab vs Placebo for Generalized Myasthenia Gravis	32
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels	32
Error in Figure 2	31
Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?	31
Risk Factors for Young-Onset Dementia in the UK Biobank	31
Error in Methods	31
Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy	31
A Funeral for a Neurologist	30
Quality Improvement Intervention for Reducing Acute Treatment Times in Ischemic Stroke	30
Inducers and Cardiovascular Risk—Potential Role for Lowered Drug Exposure	30
E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions	30
Association Between Use of Angiotensin Receptor Blockers and Incidence of Epilepsy in Patients With Hypertension—Reply	30
Light Reading—The Gravity of Postoperative Care	30
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19	29
Remembering the Physician’s Humanity—Physicians Are Humans Too	29
Neuro-Advocacy—Professionalism in Action	29
Paused—A Residency Interrupted	29
A New Dystonia Phenotype in Wilson Disease	29
Entering Medicine as a Physician and a Patient	29
Association of Tourette Syndrome and Chronic Tic Disorder With Violent Assault and Criminal Convictions	28
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms	28
Lecanemab Treatment in a Specialty Memory Clinic	28
Effect of Irrigation Fluid Temperature on Recurrence in the Evacuation of Chronic Subdural Hematoma	28
Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor	27
Multiple Facial Ulcers Following a Stroke	27
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?	27
Embedded Human Closed-Loop Deep Brain Stimulation for Tourette Syndrome	27
JAMA Neurology	27
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers	27
Gene Therapy vs Cochlear Implantation in Restoring Hearing Function and Speech Perception for Individuals With Congenital Deafness	27
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity	27
Error in Figure 2B	26
Error in Figure 1	26
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply	26
Trends in AVM-Associated Intracranial Hemorrhage in the United States, 2000-2019	26
A Decision With Love	26
Error in Title	26
How SAFE Is Real-world Use of Spinal Cord Stimulation Therapy for Chronic Pain?	26
Central Retinal Artery Occlusion With Cilioretinal Artery Sparing After Semaglutide Injection	25
Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events	25
Bilateral Calcification of the Meckel Cave Causing Hemicrania Continua	25
Anticoagulation in ESUS—Back From the Dead?	25
Abnormal Movements in Bickerstaff Brainstem Encephalitis Mimicking Anti–N-Methyl-d-Aspartate Receptor Encephalitis	25
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease	24
Combined Physiotherapy and Cognitive Behavioral Therapy for Functional Movement Disorders	24
Research Criteria for the Behavioral Variant of Alzheimer Disease	24
Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database	24
Risk Factors and Prognosis of Early Posttraumatic Seizures in Moderate to Severe Traumatic Brain Injury	24
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease	24
Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage	23
Error in Title	23
Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment for Autoimmune Diseases	23
JAMA Neurology—The Year in Review, 2023	23
JAMA Neurology	23
Errors in Results in Abstract and Text and in Table 1	23
Aducanumab and the Business of Alzheimer Disease—Some Choice	22
The Cynicism of the Seronegative	22
Functional Impairment Preceding Parkinson Disease Diagnosis—What’s in a Prodrome?	22
Sex Differences in Case-Fatality Rates of Stroke—Reply	22
Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups	22
Error in the Author Affiliations	22
Oncogenic Pathways Provide Clue to the Etiology of Human Mesial Temporal Lobe Epilepsy	22